Trial Evaluating Pfizer’s Quadrivalent mRNA Influenza Vaccine Begins
The quadrivalent modRNA influenza vaccine candidate uses mRNA technology, which requires only the genetic sequence of the virus.
Vaccines
ACIP: Updated Vaccine Guidance for the 2022-2023 Influenza Season
In general, routine annual vaccination is recommended for all patients 6 months of age and older who have no contraindications and should be completed by the end of October.
Study Shows Bivalent RSV Vaccine Candidate Provides Protection for Older Adults
The RSVpreF vaccine candidate consists of 2 prefusion F proteins selected to optimize protection against RSV A and B.
FDA Authorizes Use of Novavax COVID-19 Vaccine, Adjuvanted in Adolescents
The FDA has expanded the EUA for the Novavax COVID-19 Vaccine, Adjuvanted to include adolescents 12 to 17 years of age to prevent COVID-19.
Novavax Submits EUA Request for COVID-19 Vaccine Booster
The submission is supported by data from the phase 3 PREVENT-19 trial and the phase 2 COV-BOOST trial.
FDA Authorizes Intradermal Use of Jynneos to Increase Supply During Monkeypox Outbreak
Under the EUA, Jynneos can be administered either intradermally for individuals aged ≥18 years or subcutaneously for individuals aged <18 years.
Vaccines for Monkeypox Prevention: Jynneos and ACAM2000
An individual is considered fully vaccinated about 2 weeks after the second dose of Jynneos and 4 weeks after receiving ACAM2000.
CDC: Protein-Based Novavax COVID-19 Vaccine Recommended for Adults
The Novavax COVID-19 Vaccine, Adjuvanted is administered intramuscularly as a 2-dose primary series (0.5mL each), separated by 3 weeks.
Comirnaty Gets Full FDA Approval for COVID-19 Prevention in Adolescents
The approval was based on data from a phase 3 trial which included 2260 participants 12 to 15 years of age enrolled in the United States.
HHS Expands Access to Jynneos Vaccine in Light of Monkeypox Outbreak
In total, 1.6 million doses of the Jynneos vaccine will be available this year.
- Loading...
Loading...
Next post in Medicine
Loading... 
Loading...